Status
Conditions
Treatments
About
This feasibility performance study evaluates the ABL90 FLEX PLUS HEM device for its analytical performance in a clinical setting. The study aims to evaluate the performance of the hemolysis detection feature.
Full description
The study is designed to assess the feasibility and performance of the ABL90 FLEX PLUS HEM device in a clinical environment. It will involve testing whole blood samples using the device and comparing results against established reference method. The primary focus is on validating the device's performance of the hemolysis detection function. The study will be conducted at one selected clinical site with trained personnel and will follow a predefined protocol to ensure consistency and reliability of data collection. The outcomes will inform future clinical studies aimed at supporting regulatory submissions and clinical adoption.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subject must be 18 years of age or older
Informed consent is obtained:
Subject evaluated as suitable according to the protocol and for the study by the principal investigator or designee.
Exclusion criteria
95 participants in 1 patient group
Loading...
Central trial contact
Vadim Fedulov
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal